Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
Pages
- Home
- About Dr. Tim Sandle
- Technical articles (free)
- Publications by Tim Sandle
- Microbiology books by Tim Sandle
- Other books by Tim Sandle
- Microbiology Sites
- Presentations by Tim Sandle
- Advertise here
- Write for us
- About this site
- Science and microbiology videos
- Pharmig Publications
- Privacy Policy
- Pharma Microbiology MSc
Friday, 5 June 2020
FDA - Q3D(R1) Elemental Impurities
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
Thursday, 4 June 2020
Communities of microbes found to have working memory
Biologists
studying communities of bacteria have discovered that these so-called simple
organisms feature a robust capacity for memory. Using light, researchers were
able to encode complex memory patterns and visualize cells with memory. The
discovery reveals surprising parallels between low-level single-celled
organisms and sophisticated neurons that process memory in the human brain. The
finding also provides a starting path for scientists to one day design basic
computing systems with living organisms such as bacteria.
The
ability to encode memory in bacterial communities, the researchers say, could
enable future biological computation through the imprinting of complex spatial
memory patterns in biofilms.
See:
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
Wednesday, 3 June 2020
FDA - Safety testing of drug metabolites
This
guidance provides recommendations to industry on when and how to identify and
characterize drug metabolites whose nonclinical toxicity needs to be evaluated.
Drug metabolites may need to be determined in nonclinical studies when they are
disproportionate drug metabolites, that is, metabolites identified only in
humans or present at higher plasma concentrations in humans than in any of the
animal species used during standard nonclinical toxicology testing.
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
Tuesday, 2 June 2020
New insight into bacterial structure to help fight against superbugs
Scientists
have produced the first high-resolution images of the structure of the cell
wall of bacteria, in a study that could further understanding of antimicrobial
resistance.
The images give
unprecedented insight
into the composition of the bacterial cell wall and will inform new approaches
to developing antibiotics in order to combat antibiotic resistance. There are
no other examples of studies of the cell wall in any organism at comparable
resolution, down to the molecular scale.
The
team used an advanced microscopy technique called Atomic Force Microscopy
(AFM), which works by using a sharp needle to feel the shape of a surface and build
an image similar to a contour map, but at the scale of individual molecules.
See:
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
Monday, 1 June 2020
Technological developments with wound treatment dressings
Dressings
are long-established in the medical field for keeping wounds clean and
preventing secondary infections. Dressings are essential for reducing infection
risk; more recent advancements have seen dressings developed to promote wound
healing.
In
relation to this, Tim Sandle has written an article for Infectious Disease Hub.
Here is an extract:
This
involves the addition of physical or chemical processes designed to kill any
pathogenic microorganisms that might be present, and which pose a risk of
triggering a disease such as sepsis (where the chemicals that body’s immune
system releases into the bloodstream to combat an infection trigger inflammation
throughout the entire body) or delay the rate of wound healing (one of the
causes of delayed wound healing is the presence of microorganisms in the
wound). This article examines some of these developments, and also considers an
additional development in the form of color-changing dressings for signaling
the presence of antimicrobial-resistant bacteria.
The
reference is:
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
Saturday, 30 May 2020
Plastic eating bacterium offers pollution hope
This
newly identified strain of Pseudomonas bacteria was discovered by a team consisting
of researchers from Helmholtz Centre for Environmental Research (Leipzig,
Germany), Freiberg University of Mining and Technology (Germany) and Helmholtz
Centre for Infection Research (Braunschweig, Germany), who have demonstrated
its ability to break down polyurethane, a toxic type of plastic that is
particularly hard to recycle.
In
2015 alone, polyurethane accounted for 3.5 million tons of the plastic produced
in Europe. Its lightweight, insulating and flexible properties make it suitable
for use in many products, from shoes and refrigerators to kitchen sponges.
However, it’s incredibly difficult and energy-intensive to recycle, so most
ends up on landfill sites where it releases toxic, often carcinogenic,
chemicals.
Most
bacteria are unable to withstand the toxic fumes released by the plastic, but,
as demonstrated in a recent study published in Frontiers in Microbiology, this
newly discovered strain is able to not only withstand and survive in the harsh
environment, but also degrade some of the chemical building blocks of
polyurethane and use these for energy.
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
Monday, 18 May 2020
Ready for The Count? Back-To-Basics Review Of Microbial Colony Counting
Tim
Sandle looks at the issue of colony counting from a new perspective, including
limitations with the human eye, and with how data integrity can be improved.
The
reference is:
Sandle,
T. (2020) Ready for The Count? Back-To-Basics Review Of Microbial Colony
Counting, Journal of GxP Compliance, 24 (1) : http://www.ivtnetwork.com/article/ready-count-back-basics-review-microbial-colony-counting
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
Thursday, 14 May 2020
What type of cells does the novel coronavirus attack?
Scientists
from the Berlin Institute of Health (BIH), Charité -- Universitätsmedizin
Berlin and the Thorax Clinic at Heidelberg University Hospital, whose
collaboration is taking place under the auspices of the German Center for Lung
Research (DZL), have examined samples from non-virus infected patients to
determine which cells of the lungs and bronchi are targets for novel
coronavirus (SARS-CoV-2) infection. They discovered that the receptor for this
coronavirus is abundantly expressed in certain progenitor cells. These cells
normally develop into respiratory tract cells lined with hair-like projections
called cilia that sweep mucus and bacteria out of the lungs.
60,000
single cells were sequenced
The
researchers discovered that certain progenitor cells in the bronchi are mainly
responsible for producing the coronavirus receptors. These progenitor cells
normally develop into respiratory tract cells lined with hair-like projections
called cilia that sweep mucus and bacteria out of the lungs.
See:
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
Friday, 8 May 2020
Nosopharm develops a first-in-class novel antibiotic
Nosopharm, specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, today announces it has been granted a US patent for NOSO-502. NOSO-502 is Nosopharm’s first clinical candidate in a new class of antibiotics called Odilhorhabdins, aimed at eradicating resistant bacteria. This patent secures Nosopharm’s market exclusivity rights in the US, the leading pharmaceutical market. It also covers numerous chemical analogs - the chemical space of NOSO-502 – thereby reinforcing its protection against exploitation by competitors.
Besides the US patent (US Patent No. 10,626,144), Nosopharm has been granted a patent in Russia, and a notice of acceptance has recently been issued in Australia. In addition, the company has filed patent applications in Canada, China, Europe (EPO), Japan, Hong Kong, Brazil, South Korea, India, Israel and Mexico. Apart from Canada and South Korea, which start examining patent applications later than other countries, decisions are pending in all these territories and are expected to be announced during the course of this year.
The growing resistance of pathogenic bacteria is a threat to the efficacy of antibiotics. In 2015 antibiotic-resistant bacteria were estimated to be responsible for 670,000 infections and 33,110 attributable deaths in the EU and the European Economic Area (EEA). From a global perspective, antimicrobial resistance could kill up to ten million people every year by 2050, which could cost up to €94 trillion ($100tn).
Nosopharm investigates a new class of antibiotics, Odilhorhabdins, that inhibit the bacterial ribosome with a new mechanism of action. It is intended for treating nosocomial infections caused by Enterobacteriaceae, including polymyxin– and carbapenem-resistant Enterobacteriaceae (CRE). In 2017, the WHO published a list of priority pathogens for the development of new antibiotics. Carbapenem-resistant Gram-negative bacteria (Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii) were at the top of that list, with critical priority.
NOSO-502 has proven to be effective in vivo in Enterobacteriaceae infection models and demonstrated antibacterial activity in vitro against multi-drug resistant clinical isolates (KPC, NDM and OXA among others).
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
Saturday, 2 May 2020
Coronavirus testing, antivirals, vaccines and other measures
Posted by Dr. Tim Sandle,
Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
Sunday, 19 April 2020
EU GMP Annex 21
Annex
21 to the EU-GMP Guidelines has been published as a draft (on 20th
March 2020), titled "Importation of medicinal Products".
The Annex
is aimed at Manufacturing and Importation Authorisation holders (MIA holders)
who import human or veterinary medicinal products from third countries.
The
Annex does not cover products that do not have a marketing authorisation in the
EU/EEA and are directly re-exported.
The
Annex includes:
·
Physical
transfer from the third country to the EU/EEA
·
Certification
by the Qualified Person (QP) (link with the requirements of Annex 16)
·
Requirements
for equipment and facilities
·
Required
documentation
·
GMP
requirements for manufacturers and exporters in third countries
·
Qualification
and audits under the responsibility of the importing company and the Qualified
Person (QP)
·
Import
testing
·
Contractual
regulations between all companies or persons involved in the import
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
Saturday, 11 April 2020
Knowing more about a virus threat may not satisfy you
People who rate
themselves as highly knowledgeable about a new infectious disease threat could
also be more likely to believe they don't know enough, a new study suggests.
In the case of this
study, the infectious disease threat was the Zika virus. But the authors of the
new study, published recently in the journal Risk Analysis, say the results could apply to the recent novel coronavirus (COVID-19) outbreak.
"The Zika virus
and the coronavirus have important things in common," said Shelly Hovick,
co-author of the study and assistant professor of communication at The Ohio
State University.
"In both cases,
they are shrouded in uncertainty and have received a lot of media attention.
Our research looks at how people seek and process information when there is so
much uncertainty."
One of the key
findings of the new study: With limited information about Zika available, more
knowledge was not that comforting.
"We found that
the more people thought they knew, the more they realized they didn't know
enough," said Austin Hubner, lead author of the study and a doctoral
student in communication at Ohio State.
"With the Zika
virus, even the experts themselves didn't know much at the time. That's the
same thing we're seeing with the coronavirus, and that's scary for people who
believe they are at risk."
For the study, the
researchers conducted an online survey of 494 people of childbearing age living
in Florida in December 2016.
See:
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
Monday, 30 March 2020
Guide to sterility test isolators
An isolator is an arrangement of physical barriers that are integrated so that the workspace (an enclosed environment) within the isolator is sealed from the outside environment. Isolators provide a testing environment free from contamination, through routine sanitization using a validated cycle and confirmed by environmental monitoring.
In addition, these devices enable the isolation between the operator and the process. There are many complications with isolators, from design to qualification, and with general operation.
To address these concerns and to outline best practices, Tim Sandle has written a new Pharmig guide:
Sandle, T. (2019) Guide to sterility test isolators, Pharmig, Stanstead Abbotts: UK (ISBN 978-0-9560804-9-3)
Foe details see: https://www.pharmig.org.uk/en/products/publications/
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
Saturday, 1 February 2020
Antimicrobial resistance bacteria found in raw pet food
The fight against antimicrobial resistance has a new problem – raw
pet food, according to new research. Sales of biologically appropriate raw
food, especially for dogs, have risen in recent years.
Microbiologists working in Switzerland have assessed 51 samples of
raw diet pet food, drawn from different suppliers in stores as well as from the
Internet. The analysis revealed that some three-quarters of the food samples
contained bacteria that has the potential to trigger gastrointestinal
infections limits.
Other pathogens that have been isolated from raw pet food includes Campylobacter spp, Clostridium spp, enterotoxigenic Staphylococcus aureus, Listeria
monocytogenes, and Salmonella
spp.
According
to lead researcher Dr. Magdalena Nuesch-Inderbinen: “It is
really worrying that we found EBSL-producing bacteria in over 60 percent of
samples.”
The new research highlights a new area of concern in the battle
against antimicrobial resistance. Antimicrobial
resistance is a phenomenon the occurs naturally as bacteria respond to various
pressures within the environment. What is of concern is the worldwide
acceleration of resistance. U.S. Centers for Disease Control and Prevention (CDC)
data
finds that many high-income countries are entering a “post antibiotic
era.”
One reason for the trend is linked to the practice of animal
feed-additive antibiotic usage, which is some countries is an integral part of
animal-production technology. The reason for adding of antibiotics is for the
creation of 'leaner' meat (animals given antimicrobial tend to grow more
quickly). In addition, the indiscriminate administering of antibmicrobials to
animals is a way of side-stepping putting in place better animal hygiene
conditions. Many countries have banned
this practice, but it also continues in many other parts of the world.
The study additionally highlights concerns for pet owners when
considering to buy raw food and then how that food is handled in the home. In fact, the
American Veterinary Animal association “discourages the feeding to
cats and dogs of any animal-source protein that has not first been subjected to
a process to eliminate pathogens because of the risk of illness to cats and
dogs as well as humans.”
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology
Monday, 27 January 2020
Integrating Good Distribution Practice into the QMS
Good Distribution Practice (GDP) concerns the
distribution processes for pharmaceutical products that results in medics and
patients obtaining access to the medications required. For the pharmaceutical
organization, the distribution process occurs both upstream and downstream.
Upstream are the suppliers who create goods and services used in a
manufacturer’s own operations, such as raw components or materials. The
downstream supply chain efficiently distributes a company’s products or
services to its customers. Each stage, both upstream and downstream, needs to
be proactively managed to minimize quality, as well as financial,
confidentiality, operational, reputational and legal risks.
Tim Sandle has written a chapter for the book GoodDistribution Practice: A Handbook for Healthcare Manufacturers and Suppliers.
Here is an extract:
GDP requirements are designed to codify and to
structure the processes. These requirements bear close similarity to the
requirements set out in Good Manufacturing Practice (GMP) regulations. The
primary difference is that GDP covers the wholesale distribution of medicines,
whereas GMP covers their manufacture.
There overlap between the two rest with the need to maintain product
quality after a batch has been released from the manufacturing site, as well as
the necessity to monitor and control complaints, address problems, and have a
system in place to enact a recall.
In assessing the requirements for GDP, there are
different national and supranational standards. In the US GMP is based on the
Code of Federal Regulations 21 CFR 210/211, with additional guidance contained
within USP chapter 1079 “Good Storage and Distribution Practices for Drug
Products.” (USP, 2018) There is an additional USP chapter of interest, chapter
1197 “Good Distribution Practices for Pharmaceutical Excipients” (USP, 2018b).
For Europe GDP is based on the Directive of the Board of the European Community
92/25/EEC regarding the wholesale distribution of drugs for human consumption,
supported by guideline 2015/C 95/01 (European Commission, 2015), and the
Falsified Medicines Directive (European Commission, 2011), which requires a
unique identifier and an anti-tampering device to allow the verification of the
authenticity of medicinal products. With the World Health Organization, the
applicable text is Annex 5 of the WHO recommendations “good distribution
practices for pharmaceutical products.” (WHO, 2010a) One commonality through
these regulations and following on from items raised during pharmaceutical
organization inspections, is with a focus on serialization. This has required
for new strategies, processes, and technologies that allow for a business to,
at any time, pinpoint the location and origin of any single drug.
The reference is:
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology
Subscribe to:
Posts (Atom)





